Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/20/2010

NEW YORK and JERUSALEM, Sept. 21 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Wednesday, September 22, 2010 at 11:00 AM (ET).

Chiasma is currently conducting its second clinical trial of the investigational new drug Octreolin™, an oral form of octreotide acetate that uses the proprietary Transient Permeability Enhancer (TPE) system for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  A third clinical trial is planned to start by the end of 2010. The Food and Drug Administration has granted orphan drug designation for Octreolin and the Company will submit an application for Orphan Medicinal Product Designation to the European Medicines Agency (EMA) shortly.

Upon receipt of positive Phase 3 efficacy and safety data, the Company will submit an NDA using the "505(b)(2) regulatory pathway" in the United States and its equivalent, the "Hybrid Application," in Europe.

Chiasma is also developing Octreolin as a potential treatment for patients with portal hypertension (PHT); there are currently no drugs approved for PHT in the U.S.

About Chiasma

Chiasma is evaluating the TPE technology with approved drugs, which may enable their being switched from injectable to oral, and potentially may also result in new indications or otherwise improved labels.  The TPE technology promotes the delivery of drugs to the GI wall and from there to the liver.  It is applicable to macromolecules that, to date, can be administered only by injection.  TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.  The Company has successfully demonstrated proof-of-principle in delivering small proteins, peptides, saccharides and heretofore-insoluble small molecules via the oral route.

The Company is backed by ARCH Venture Partners, MPM Capital, F2 Ventures, 7 Health Ventures and the MPM Novartis Strategic Fund. Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events o otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
2. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
3. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
4. Caliper Life Sciences CEO to Present Keynote Presentation at MipTec European Conference
5. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
8. CryoLife to Present at UBS Global Life Sciences Conference
9. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ., ... artificial intelligence, real-time decision support tools in the emergency room, ... the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology Week, ... David Intercontinental Hotel in Tel Aviv, Israel ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has ... 2017 and Beyond. The paper outlines the key trends that are creating both ... “We’ve witnessed a lot of highs and lows as the precision agriculture market ...
(Date:5/23/2016)... Springs, North Carolina (PRWEB) , ... May 23, ... ... process automation and building management solutions and services based in Aurora, Ohio, has ... decade of established business in the Research Triangle Park area, this new location ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):